Natural selection of tumor variants in the generation of “tumor escape” phenotypes

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.

Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J., Lanier, L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 3,272

IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896

Inhibition of death receptor signals by cellular FLIP

Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.-L., Schröter, M., Burns, K., Mattmann, C., et al. (1997) · Nature · doi:10.1038/40657 · Cited by 2,548

A cell culture model for T lymphocyte clonal anergy

Schwartz, R. H. (1990) · Science · doi:10.1126/science.2113314 · Cited by 1,857

Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance

Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y., & Sakaguchi, S. (2002) · Nature Immunology · doi:10.1038/ni759 · Cited by 1,729

Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance

Sakaguchi, S., Sakaguchi, N., Shimizu, J., Yamazaki, S., Sakihama, T., Itoh, M., Kuniyasu, Y., Nomura, T., Toda, M., & Takahashi, T. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820102.x · Cited by 1,505

Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice

Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465

CD4+CD25+ Immunoregulatory T Cells

McHugh, R. S., Whitters, M. J., Piccirillo, C. A., Young, D. A., Shevach, E. M., Collins, M., & Byrne, M. C. (2002) · Immunity · doi:10.1016/s1074-7613(02)00280-7 · Cited by 1,395

Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape

Hahne, M., Rimoldi, D., Schröter, M., Romero, P. J., Schreier, M. H., French, L. E., Schneider, P., Bornand, T., Fontana, A., Liénard, D., et al. (1996) · Science · doi:10.1126/science.274.5291.1363 · Cited by 1,236

Model of the developing tumorigenic phenotype in mammalian cells and the roles of sustained stress and replicative senescence

Karpinets, T. V., & Foy, B. D. (2004) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2003.11.005 · Cited by 15

Association between cancer immunity and treatment results in uterine cervical cancer patients treated with radiotherapy

Someya, M., Tsuchiya, T., Fukushima, Y., Hasegawa, T., Takada, Y., Hori, M., Miura, K., Kitagawa, M., Gocho, T., Hirohashi, Y., et al. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa149 · Cited by 16

Modulation of Tumor Immunity by Soluble and Membrane-Bound Molecules at the Immunological Synapse

González, P. A., Carreño, L. J., Céspedes, P. F., Bueno, S. M., Riedel, C. A., & Kalergis, A. M. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/450291 · Cited by 16

Evidence of macrophage and lymphocyte, but not dendritic cell, infiltration in posterior uveal melanomas, whilst cultured uveal melanomas demonstrate pluripotency by expressing CD68 and CD163

Woodward, J. K. L., Sisley, K., Reeves, G. M. B., Nichols, C. E., Parsons, M. A., Mudhar, H. S., & Rennie, I. G. (2004) · International Journal of Experimental Pathology · doi:10.1111/j.0959-9673.2004.00370.x · Cited by 16

Cat and mouse games

Melief, C. J. M. (2005) · Nature · doi:10.1038/437041a · Cited by 16

Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines

Hushmandi, K., Fooladi, A. A. I., Reiter, R. J., Farahani, N., Liang, L., Aref, A. R., Nabavi, N., Alimohammadi, M., Liu, L., & Sethi, G. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00662-3 · Cited by 16

LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy

Luo, L., Fu, S., Du, W. T., He, L.-N., Zhang, X., Wang, Y., Zhou, Y., & Hong, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.959868 · Cited by 16

Induced pluripotency as a potential path towards iNKT cell-mediated cancer immunotherapy

Watarai, H., Yamada, D., Fujii, S., Taniguchi, M., & Koseki, H. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1091-0 · Cited by 15

Antitumor Effect of Embryonic Stem Cells in a Non-Small Cell Lung Cancer Model: Antitumor Factors and Immune Responses

Dong, W., Qiu, C., Shen, H., Liu, Q., & Du, J. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.6538 · Cited by 14

Methylcholanthrene-Induced Sarcomas Develop Independently from NOX2-Derived ROS

Ligtenberg, M. A., Çınar, Ö., Holmdahl, R., Mougiakakos, D., & Kiessling, R. W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129786 · Cited by 15

Tumor resistance to specific lysis: A major hurdle for successful immunotherapy of cancer

Chouaı̈b, S., Meslin, F., Thiery, J., & Mami‐Chouaib, F. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.08.020 · Cited by 15

The Role of T Lymphocytes in Cancer Patients Undergoing Immunotherapy with Autologous Dendritic Cells

Rodrigues, C. M., Matias, B. F., Murta, E. F. C., & Michelin, M. A. (2011) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s6927 · Cited by 15

Novel Treatments in Development for Melanoma

Bernatchez, C., Cooper, Z. A., Wargo, J. A., Hwu, P., & Lizee, G. A. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_16 · Cited by 15

Loss of Tff1 Promotes Pro-Inflammatory Phenotype with Increase in the Levels of RORγt+ T Lymphocytes and Il-17 in Mouse Gastric Neoplasia

Soutto, M., Saleh, M. A., Arredouani, M. S., Piazuelo, B. M., Belkhiri, A., & El-Rifai, W. M. (2017) · Journal of Cancer · doi:10.7150/jca.19639 · Cited by 15

Host response to immune checkpoint inhibitors contributes to tumor aggressiveness

Khononov, I., Jacob, E., Fremder, E., Dahan, N., Harel, M., Raviv, Z., Krastev, B. M., & Shaked, Y. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001996 · Cited by 15

CCL27 Signaling in the Tumor Microenvironment

Martínez-Rodríguez, M., & Monteagudo, C. C. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-62658-7_9 · Cited by 15

Recent advances in targeting protein degradation for tumor immunotherapy

Li, S., Jin, Y., Wu, H., Yuan, H., & Zhao, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01765-4 · Cited by 14

Regulatory T cells in the actinic cheilitis

Gasparoto, T. H., Malaspina, T. S. D. S., Damante, J. H., Mello, E. J. F., Ikoma, M. R. V., Garlet, G. P., Nogueira, M. R. S., Cavassani, K. A., Silva, J. S., & Campanelli, A. P. (2014) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12207 · Cited by 14

From cell biology to immunology: Controlling metastatic progression of cancer via microRNA regulatory networks

Park, J. H., Τheodoratou, E., Călin, G. A., & Shin, J. I. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1230579 · Cited by 14

Display of CCL21 on cancer cell membrane through genetic modification using a pH low insertion peptide

Li, S., Wang, Y., Jiang, H., Bai, Y., Chen, T., Chen, M., Ma, M., Yang, S., Wu, Y., Shi, C., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.124324 · Cited by 14

Nanoliposomal VEGF-R2 peptide vaccine acts as an effective therapeutic vaccine in a murine B16F10 model of melanoma

Zahedipour, F., Zamani, P., Mashreghi, M., Astaneh, M., Sankian, M., Amiri, A., Jamialahmadi, K., & Jaafari, M. R. (2023) · Cancer Nanotechnology · doi:10.1186/s12645-023-00213-7 · Cited by 14

Immunotherapy for head and neck cancer: Fundamentals and therapeutic development

Okano, S. (2024) · Auris Nasus Larynx · doi:10.1016/j.anl.2024.05.001 · Cited by 15

Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity

Vanpouille‐Box, C., & Hindré, F. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00136 · Cited by 16

Immunotherapy in colorectal cancer treatment: actual landscape and future perspectives

Bittoni, A., Sotte, V., Meletani, T., Cantini, L., Giampieri, R., & Berardi, R. (2018) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2018.37 · Cited by 14

The Potential of Tumor Debulking to Support Molecular Targeted Therapies

Oppel, F., Görner, M., & Sudhoff, H. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00801 · Cited by 14

Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Tsimberidou, A. M., Guenther, K., Andersson, B. S., Mendrzyk, R., Alpert, A., Wagner, C., Nowak, A., Aslan, K., Satelli, A., Richter, F., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0444 · Cited by 14

Cancer Immunoediting

Teng, M. W. L., Kershaw, M. H., & Smyth, M. J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00007-5 · Cited by 14

Improving TCR Gene Therapy for Treatment of Haematological Malignancies

Nicholson, E., Ghorashian, S., & Stauss, H. J. (2012) · Advances in Hematology · doi:10.1155/2012/404081 · Cited by 15

A high throughput method for enrichment of natural killer cells and lymphocytes and assessment of in vitro cytotoxicity

So, E. C., Sallin, M. A., Zhang, X., Chan, S. L., Sahni, L., Schulze, D. H., Dávila, E., Strome, S. E., & Jain, A. K. (2013) · Journal of Immunological Methods · doi:10.1016/j.jim.2013.05.001 · Cited by 13

A Race between Tumor Immunoescape and Genome Maintenance Selects for Optimum Levels of (epi)genetic Instability

Iwami, S., Haeno, H., & Michor, F. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002370 · Cited by 14

Immune Checkpoint Therapy in Head and Neck Cancers

Msaouel, P., & Massarelli, E. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000180 · Cited by 14

Simultaneousin vitrogeneration of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia

Sohn, H., Lee, J. Y., Lee, H.-J., Sohn, D.-H., Cho, H.-I., Kim, H., & Kim, T. (2017) · Oncotarget · doi:10.18632/oncotarget.17212 · Cited by 14

BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?

Ee, T. J. V., Acker, H. H. V., van Oorschot, T. G. M., Tendeloo, V. F. V., Smits, E., Bakdash, G., Schreibelt, G., & de Vries, I. J. M. (2018) · Vaccines · doi:10.3390/vaccines6030065 · Cited by 14

Walker 256 tumor MHC class I expression during the shift from A variant to the immunogenic AR variant

Schanoski, A. S., Cavalcanti, T. C. S., de Campos, C. B. L., Vieira-Matos, A. N., Rettori, O., & Guimarães, F. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.01.023 · Cited by 14

Possible Allogeneic Graft-Versus-Tumor Effect in Childhood Melanoma

Kasow, K. A., Handgretinger, R., Krasin, M. J., Pappo, A. S., & Leung, W. H. (2003) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200312000-00016 · Cited by 14

A Rare Transporter Associated with Antigen Processing Polymorphism Overpresented in HLAlow Colon Cancer Reveals the Functional Significance of the Signature Domain in Antigen Processing

Yang, T., Lapinski, P. E., Zhao, H., Zhou, Q., Zhang, H., Raghavan, M., Liu, Y., & Zheng, P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1804 · Cited by 14

Nanomedicines Targeting Tumor Cells or Tumor-Associated Macrophages for Combinatorial Cancer Photodynamic Therapy and Immunotherapy: Strategies and Influencing Factors

Wei, Y., Li, R., Wang, Y., Fu, J., Liu, J., & Ma, X. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s466315 · Cited by 13

Xenovaccinotherapy for melanoma.

Seledtsov, V. I., Shishkov, A. A., Surovtseva, M., Самарин, Д. М., Seledtsova, G. V., Niza, N. A., & Seledtsov, D. V. (2006) · PubMed · Cited by 13

Combination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells

Kim, S., Ha, G., Kim, S., & Kang, C. (2013) · Immunological Investigations · doi:10.3109/08820139.2013.857352 · Cited by 13

Mangiferin induces immune responses and evaluates the survival rate in WEHI‐3 cell generated mouse leukemia in vivo

Shang, H., Chen, C., Shih, Y., Peng, S., Chen, Y., Liu, K., Huang, H., Hsueh, S., Chen, K., Lu, H., et al. (2021) · Environmental Toxicology · doi:10.1002/tox.23013 · Cited by 13

The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma

Helgadóttir, H., Andersson, E. K., Villabona, L. E. E., Kanter, L., van der Zanden, H., Haasnoot, G. W., Seliger, B., Bergfeldt, K., Hansson, J., Ragnarsson-Olding, B. K., et al. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0669-8 · Cited by 13

VRP immunotherapy targeting neu: treatment efficacy and evidence for immunoediting in a stringent rat mammary tumor model

Laust, A. K., Sur, B. W., Wang, K., Hubby, B., Smith, J., & Nelson, E. L. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9517-8 · Cited by 13

In Situ Conversion of Melanoma Lesions into Autologous Vaccine by Intratumoral Injections of α-gal Glycolipids

Galili, U., Albertini, M. R., Sondel, P. M., Wigglesworth, K., Sullivan, M. E., & Whalen, G. F. (2010) · Cancers · doi:10.3390/cancers2020773 · Cited by 13

Circulating Regulatory T Cells in Endometrial Cancer: A Role for Age and Menopausal Status

Sawan, S., Burt, D. J., Stern, P. L., Holland, C. M., & Elkord, E. (2010) · Immunological Investigations · doi:10.3109/08820139.2010.513022 · Cited by 12

Cachexia induced by Walker 256 tumor growth causes rat lymphocyte death

de Lima, T. M., Lima, M. M. R., de Almeida, D. C. G., Mendonça, J. R., & Curi, R. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0570-4 · Cited by 13

The Interaction Mode of Premalignant Schwann and Immune Effector Cells during Chemically Induced Carcinogenesis in the Rat Peripheral Nervous System Is Strongly Influenced by Genetic Background

Gering, K. M., Marx, J., Lennartz, K., Fischer, C., Rajewsky, M. F., & Kindler‐Röhrborn, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3780 · Cited by 13

Proteasome-inhibited dendritic cells demonstrate improved presentation of exogenous synthetic and natural HLA-class I peptide epitopes

Chromik, J., Schnürer, E., Meyer, R. G., Wehler, T., Tüting, T., Wölfel, T., Huber, C., & Herr, W. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.09.021 · Cited by 13

A different pattern of cytotoxic T lymphocyte recognition against primary and metastatic tumor cells in a patient with nonsmall cell lung carcinoma

So, T., Takenoyama, M., Ichiki, Y., Mizukami, M., So, T., Hanagiri, T., Sugio, K., & Yasumoto, K. (2004) · Cancer · doi:10.1002/cncr.20782 · Cited by 13

Local delivery of poxvirus vaccines for melanoma

Hörig, H., & Kaufman, H. L. (2003) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.09.005 · Cited by 13

Fusokine Interleukin-2/Interleukin-18, a Novel Potent Innate and Adaptive Immune Stimulator with Decreased Toxicity

Acres, B., Gantzer, M., Remy, C., Futin, N., Accart, N., Chaloin, O., Hoebeke, J., Balloul, J., & Paul, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0691 · Cited by 13

Genome instability and crosstalk with the immune response

Chabanon, R. M., Danlos, F. X., Ouali, K., & Postel-Vinay, S. C. (2025) · Genome Medicine · doi:10.1186/s13073-025-01509-6 · Cited by 16

Transcriptomic insights into adenoid cystic carcinoma via RNA sequencing

Tang, Y., An, P.-G., Gu, B., Yi, S., Hu, X., Wu, W., & Zhang, J. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1144945 · Cited by 12

Recent advances in AIE-based platforms for cancer immunotherapy

Chen, Z., Li, X., Liu, Q., Li, W., Wang, T., & Ding, D. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.09.041 · Cited by 12

T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients

Tüting, T. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12111 · Cited by 12

Induction of Antitumor Immune Response by Homeostatic Proliferation and CD28 Signaling

Suzuki, T., Ogawa, S., Tanabe, K., Tahara, H., Abe, R., & Kishimoto, H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4596 · Cited by 12

Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity

Cormary, C., Hiver, E., Mariamé, B., Favre, G., & Tilkin‐Mariamé, A. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700861 · Cited by 12

Flt3-L gene therapy enhances immunocytokine-mediated antitumor effects and induces long-term memory

Neal, Z. C., Sondel, P. M., Bates, M. K., Gillies, S. D., & Herweijer, H. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0320-5 · Cited by 12

Nanomedicine-based cancer immunotherapy: a bibliometric analysis of research progress and prospects

Chen, C., Yuan, P., & Zhang, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1446532 · Cited by 12

Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)

Ishii, K., & Barrett, A. J. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715616544 · Cited by 12

Analysis of tumour ecological balance reveals resource-dependent adaptive strategies of ovarian cancer

Nawaz, S., Trahearn, N., Heindl, A., Banerjee, S. N., Maley, C. C., Sottoriva, A., & Yuan, Y. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.001 · Cited by 11

Phenotypic and genotypic infidelity in B-lineage neoplasms, including transdifferentiation following targeted therapy: Report from the 2021 SH/EAHP Workshop

Goodlad, J. R., Xiao, W., Amador, C. C., Cook, J. R., Happ, L. E., Thakkar, D., Davé, S. S., Doǧan, A., Duffield, A. S., Nejati, R., et al. (2023) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqad035 · Cited by 11

Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia

Foster, A. E., Brenner, M. K., & Dotti, G. (2008) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2008.08.002 · Cited by 11

Surface expression of anti‐CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A‐engineered human umbilical cord mesenchymal stem cells

Zhang, Q., Yuan, X., Lu, Y., Li, Z., Bao, S., Zhang, X., Yang, Y., Fan, D., Zhang, Y., Wu, C., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30846 · Cited by 11

Analysis of Vaccine-Induced T Cells in Humans with Cancer

Slezak, S. L., Worschech, A., Wang, E., Stroncek, D. F., & Marincola, F. M. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6451-9_14 · Cited by 11

Immunobiology of Melanoma

Phoon, Y. P., Tannenbaum, C. S., & Diaz-Montero, C. M. (2021) · Clinics in Plastic Surgery · doi:10.1016/j.cps.2021.06.005 · Cited by 12

Tumor Escape Mutants Develop within an Immune-Privileged Environment in the Absence of T Cell Selection

Chen, P. W., Uno, T., & Ksander, B. R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.162 · Cited by 11

Accumulation of CD8+ T Cells in Advanced-Stage Tumors and Delay of Disease Progression following Secondary Immunization against an Immunorecessive Epitope

Ryan, C. M., & Schell, T. D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.255 · Cited by 11

Dendritic cell-based immunotherapy for cancer and relevant challenges for transfusion medicine

VOSS, C., ALBERTINI, M., & Malter, J. S. (2004) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2004.03.005 · Cited by 11

Chemokines in Tumor Immunotherapy

Flanagan, K. (2006) · Frontiers in bioscience · doi:10.2741/1860 · Cited by 11

Impact of p53-based immunization on primary chemically-induced tumors

Cicinnati, V. R., Dworacki, G., Albers, A. E., Beckebaum, S., Tüting, T., Kaczmarek, E., & DeLeo, A. B. (2004) · International Journal of Cancer · doi:10.1002/ijc.20686 · Cited by 11

Antibodies Against Muscarinic Receptors in Breast Cancer: Agonizing Tumor Growth

Fiszman, G. L., & Sales, M. E. (2008) · Current Immunology Reviews · doi:10.2174/157339508785160732 · Cited by 11

The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides

Zhang, X., Zhang, Y., Huang, Y., Qu, P., Ma, B., Si, S., Li, Z., Li, W.-X., Li, X., Ge, W., et al. (2008) · Oncology Reports · doi:10.3892/or.20.1.245 · Cited by 11

Targeting the TCR signaling checkpoint: a therapeutic strategy to reactivate memory T cells in the tumor microenvironment

Simpson-Abelson, M. R., & Bankert, R. B. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.4.477 · Cited by 11

Considerations on clinical use of T cell immunotherapy for cancer.

Plautz, G. E., Cohen, P. A., & Shu, S. (2003) · PubMed · Cited by 11

Understanding the response to immunotherapy in humans

Wang, E., Panelli, M. C., & Marincola, F. M. (2005) · Springer Seminars in Immunopathology · doi:10.1007/s00281-004-0198-7 · Cited by 11

Functional expression of human‐epidermal‐growth‐factor receptor in a melanoma cell line

Díaz, A., Suarez, E., Blanco, R., Badia, T., Rivero, D. A., López‐Requena, A., López, A., & Montero, E. (2007) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20070009 · Cited by 11

New advances in pharmaceutical strategies for sensitizing anti‐PD ‐1 immunotherapy and clinical research

Jiang, M., Qin, B., Li, X., Liu, Y., Guan, G., & You, J. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1837 · Cited by 10

Tumor-derived extracellular vesicles: how they mediate glioma immunosuppression

Ma, T., Su, G., Wu, Q., Shen, M., Feng, X., & Zhang, Z. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-09196-5 · Cited by 12

A difficult diagnosis of H odgkin lymphoma due to immune thrombocytopenia

Marino, S., Cataldo, A. D., Magro, G. G., D’Amico, S., Spina, M. L., Benedetto, V. D., Meli, M., Moscheo, C., & Russo, G. M. (2015) · Clinical Case Reports · doi:10.1002/ccr3.176 · Cited by 10

Immunotherapy in Acute Leukemia

Leung, W. H. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.09.004 · Cited by 10

Identification of a lung cancer antigen evading CTL attack due to loss of human leukocyte antigen (HLA) class I expression

Baba, T., Hanagiri, T., Takenoyama, M., Shiota, H., Kuroda, K., Shigematsu, Y., Ichiki, Y., Uramoto, H., So, T., & Yasumoto, K. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01659.x · Cited by 10

HMGB1 suppresses colon carcinoma cell apoptosis triggered by co‑culture with dendritic cells via an ER stress‑associated autophagy pathway

Zheng, Y., & Zhu, G. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.8202 · Cited by 10

Evolving role of immunotherapy in head-and-neck cancers: A systemic review

Chanana, R., Noronha, V., Joshi, A., Patil, V., & Prabhash, K. (2018) · Journal of Head & Neck Physicians and Surgeons · doi:10.4103/jhnps.jhnps_10_18 · Cited by 10

Expression analysis of secreted and cell surface genes of five transformed human cell lines and derivative xenograft tumors

Stull, R. A., Tavassoli, R., Kennedy, S., Osborn, S. D., Harte, R., Lü, Y., Napier, C., Abo, A., & Chin, D. J. (2005) · BMC Genomics · doi:10.1186/1471-2164-6-55 · Cited by 10

Conversion of Tumors into Autologous Vaccines by Intratumoral Injection of α -Gal Glycolipids that Induce Anti-Gal/ α -Gal Epitope Interaction

Galili, U. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/134020 · Cited by 10

Induction of autoantibody production but not autoimmune disease in HEL transgenic mice vaccinated with HEL in combination with CpG or control oligodeoxynucleotides

Wang, Y., & Krieg, A. Μ. (2004) · Vaccine · doi:10.1016/j.vaccine.2003.11.055 · Cited by 10

RepSox Slows Decay of CD34+ Acute Myeloid Leukemia Cells and Decreases T Cell Immunoglobulin Mucin-3 Expression

Jajosky, A. N., Coad, J. E., Vos, J. A., Martin, K. H., Senft, J. R., Wenger, S. L., & Gibson, L. F. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2013-0193 · Cited by 10

Autologous Tumor Rejection in Humans: Trimming the Myths

Wang, E., Panelli, M. C., & Marincola, F. M. (2006) · Immunological Investigations · doi:10.1080/08820130600762385 · Cited by 10

Autofluorescence flow sorting of breast cancer cell metabolism

Shah, A. T., Cannon, T. M., Higginbotham, J. N., Coffey, R. J., & Skala, M. C. (2016) · Journal of Biophotonics · doi:10.1002/jbio.201600128 · Cited by 11

Antigenic Essence: Upgrade of Cellular Cancer Vaccines

Lokhov, P. G., & Balashova, E. E. (2021) · Cancers · doi:10.3390/cancers13040774 · Cited by 10

Preparation of purified lymphoma cells suitable for therapy

Lui, G., Manches, O., Chaperot, L., Ducrot, T., Molens, J., Sotto, J. J., Bensa, J., & Plumas, J. (2004) · Cytotherapy · doi:10.1080/14653240410006059 · Cited by 10

Strategies of Antigen-Specific T-Cell–Based Immunotherapy for Cancer

Liu, S., Zhang, M., & Zhang, W. (2005) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2005.20.491 · Cited by 10

MHC-I and PD-L1 Expression is Associated with Decreased Tumor Outgrowth and is Radiotherapy-inducible in the Murine Head and Neck Squamous Cell Carcinoma Model MOC1

Boreel, D. F., Sandker, G. W., Ansems, M., van den Bijgaart, R. J. E., Peters, J. P. W., Span, P. N., Adema, G. J., Heskamp, S., & Bussink, J. (2024) · Molecular Imaging and Biology · doi:10.1007/s11307-024-01934-w · Cited by 9

Tumor microenvironment-based signatures distinguish intratumoral heterogeneity, prognosis, and immunogenomic features of clear cell renal cell carcinoma

Anwaier, A., Xu, W., Liu, W., Wei, S., Tian, X., Qu, Y., Yang, J., Zhang, H., & Ye, D. (2023) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2023.08.003 · Cited by 9

T cell immunoglobulin domain and mucin domain-3 as an emerging target for immunotherapy in cancer management

Jinushi, M., & Yoneda, A. (2013) · ImmunoTargets and Therapy · doi:10.2147/itt.s38296 · Cited by 9

Chimeric T Cells for Adoptive Immunotherapy of Cancer: Using What Have We Learned to Plan for the Future

Peinert, S., Kershaw, M. H., & Prince, H. M. (2009) · Immunotherapy · doi:10.2217/imt.09.69 · Cited by 9

HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients

Wang, J., Liu, L., Qu, Y., Xi, W., Xia, Y., Bai, Q., Xiong, Y., Long, Q., Xu, J., & Guo, J. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2064-1 · Cited by 9

Immune biomarkers for predicting response to adoptive cell transfer as cancer treatment

van Belzen, I. A. E. M., & Keşmir, C. (2018) · Immunogenetics · doi:10.1007/s00251-018-1083-1 · Cited by 9

Biological Therapy with Complementary and Alternative Medicine in Innocuous Integrative Oncology: A Case of Cervical Cancer

Chizenga, E. P., & Abrahamse, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050626 · Cited by 9

What Are the Roles of Proprotein Convertases in the Immune Escape of Tumors?

Mehranzadeh, E., Crende, O., Badiola, I., & García-Gallastegui, P. (2022) · Biomedicines · doi:10.3390/biomedicines10123292 · Cited by 9

Michor F: A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability

Iwami, S., Haeno, H., & Franziska Michor, A. (2016)

A Race between Tumor Immunoescape and Genome Maintenance Selects for Optimum Levels of (epi)genetic Instability

Iwami, S., Haeno, H., & Michor, F. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002370 · Cited by 14

Immunotherapy and immunoselection ? tumour escape as the final hurdle

Pawelec, G. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.02.091 · Cited by 30

Strategies for tumor immune escape

Piemonti, L., Zerbi, A., & Carlo, V. D. (2003) · Drugs of today · doi:10.1358/dot.2003.39.9.799478 · Cited by 8

Abstract 4034: Immunotherapy generates selective pressure to create an escape tumor with increased susceptibility to treatment with T cell based therapies

Pan, J. H., Vodnala, S. K., Eil, R. L., Yu, Z., Gartner, J. J., Clever, D. C., Roychoudhuri, R., Patel, S. J., Klebanoff, C. A., Sukumar, M., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-4034